Общество доказательной неврологии
Личный кабинет
Поиск
Личный кабинет

Список использованной литературы

  1. Akbar, U. McQueen, R. B. Bemski, J. Carter, J. Goy, E. R. Kutner, J. Johnson, M. J. Miyasaki, J. M. & Kluger, B. (2021). Prognostic predictors relevant to end-of-life palliative care in Parkinson’s disease and related disorders: a systematic review. Journal of Neurology, Neurosurgery, and Psychiatry, 92(6), 629–636. https://doi.org/10.1136/JNNP-2020–323939,

  2. Armstrong, M. J. Litvan, I. Lang, A. E. Bak, T. H. Bhatia, K. P. Borroni, B. Boxer, A. L. Dickson, D. W. Grossman, M. Hallett, M. Josephs, K. A. Kertesz, A. Lee, S. E. Miller, B. L. Reich, S. G. Riley, D. E. Tolosa, E. Tröster, A. I. Vidailhet, M. & Weiner, W. J. (2013). Criteria for the diagnosis of corticobasal degeneration. Neurology, 80(5), 496–503.https://doi.org/10.1212/WNL. 0B013E31827F0FD1,

  3. Bhatti, K. S. Sun, C. E. & Walker, I. (2025). Corticobasal Degeneration. StatPearls. https://pubmed.ncbi.nlm.nih.gov/39937946/

  4. Buchholz, S. & Zempel, H. (2024). The six brain-specific TAU isoforms and their role in Alzheimer’s disease and related neurodegenerative dementia syndromes. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 20(5), 3606–3628. https://doi.org/10.1002/ALZ. 13784

  5. Cho, J. W. & Lee, J. H. (2014). Suppression of Myoclonus in Corticobasal Degeneration by Levetiracetam. Journal of Movement Disorders, 7(1), 28. https://doi.org/10.14802/JMD. 14007

  6. CH, van D. CJ, S. P, A. RJ, B. C, C. M, G. M, K. D, L. L, R. S, C. L, F. S, K. M, S. B, V. D, W. S, D. M, I. LD, K. & T, I. (2023). Lecanemab in Early Alzheimer’s Disease. The New England Journal of Medicine, 388(1), 142–143. https://doi.org/10.1056/NEJMOA2212948,

  7. Constantinides, V. C. Paraskevas, G. P. Paraskevas, P. G. Stefanis, L. & Kapaki, E. (2019). Corticobasal degeneration and corticobasal syndrome: A review. Clinical Parkinsonism and Related Disorders, 1,66–71. https://doi.org/10.1016/j.prdoa. 2019.08.005

  8. Courade, J. P. Angers, R. Mairet-Coello, G. Pacico, N. Tyson, K. Lightwood, D. Munro, R. McMillan, D. Griffin, R. Baker, T. Starkie, D. Nan, R. Westwood, M. Mushikiwabo, M. L. Jung, S. Odede, G. Sweeney, B. Popplewell, A. Burgess, G. … Citron, M. (2018). Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau. Acta Neuropathologica, 136(5), 729. https://doi.org/10.1007/S00401–018–1911–2,

  9. Dam, T. Boxer, A. L. Golbe, L. I. Höglinger, G. U. Morris, H. R. Litvan, I. Lang, A. E. Corvol, J. C. Aiba, I. Grundman, M. Yang, L. Tidemann-Miller, B. Kupferman, J. Harper, K. Kamisoglu, K. Wald, M. J. Graham, D. L. Gedney, L. O’Gorman, J. & Haeberlein, S. B. (2021). Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine, 27(8), 1451–1457. https://doi.org/10.1038/S41591–021–01455-X,

  10. DeVos, S. L. Miller, R. L. Schoch, K. M. Holmes, B. B. Kebodeaux, C. S. Wegener, A. J. Chen, G. Shen, T. Tran, H. Nichols, B. Zanardi, T. A. Kordasiewicz, H. B. Swayze, E. E. Bennett, C. F. Diamond, M. I. & Miller, T. M. (2017). Tau Reduction Prevents Neuronal Loss and Reverses Pathological Tau Deposition and Seeding in Mice with Tauopathy. Science Translational Medicine, 9(374), eaag0481. https://doi.org/10.1126/SCITRANSLMED. AAG0481,

  11. Dickson D. W. Bergeron C. Chin S. S.et al. Office of rare diseases neuro — pathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002; 61(11): 935–946. DOI: 10.1093/jnen/61.11.935. PMID: 12430710,

  12. Erbetta, A. Mandelli, M. L. Savoiardo, M. Grisoli, M. Bizzi, A. Soliveri, P. Chiapparini, L. Prioni, S. Bruzzone, M. G. & Girotti, F. (2009). Diffusion Tensor Imaging Shows Different Topographic Involvement of the Thalamus in Progressive Supranuclear Palsy and Corticobasal Degeneration. AJNR: American Journal of Neuroradiology, 30(8), 1482. https://doi.org/10.3174/AJNR. A1615,

  13. Erkkinen, M. G. Kim, M. O. & Geschwind, M. D. (2018). Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harbor Perspectives in Biology, 10(4). https://doi.org/10.1101/CSHPERSPECT. A033118,

  14. Grijalvo-Perez, A. M. & Litvan, I. (2014). Corticobasal degeneration. Seminars in Neurology, 34(2), 160–173. https://doi.org/10.1055/S-0034–1381734,

  15. Grigorieva, V. N. (2015). Classification and diagnosis of apraxia. Zhurnal Nevrologii i Psihiatrii Imeni S. S. Korsakova, 115(Special Issue 6), 26–35.ttps://doi.org/10.17116/JNEVRO20151156226–35

  16. Hassan, A. Whitwell, J. L. Boeve, B. F. Jack, C. R. Parisi, J. E. Dickson, D. W. & Josephs, K. A. (2010). Symmetric corticobasal degeneration (S-CBD). Parkinsonism and Related Disorders, 16(3), 208–214. https://doi.org/10.1016/j.parkreldis. 2009.11.013,

  17. Horie, K. Barthélemy, N. R. Spina, S. VandeVrede, L. He, Y. Paterson, R. W. Wright, B. A. Day, G. S. Davis, A. A. Karch, C. M. Seeley, W. W. Perrin, R. J. Koppisetti, R. K. Shaikh, F. Lago, A. L. Heuer, H. W. Ghoshal, N. Gabelle, A. Miller, B. L. … Sato, C. (2022). CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nature Medicine, 28(12), 2547. https://doi.org/10.1038/S41591–022–02075–9,

  18. Koga, S. Josephs, K. A. Aiba, I. Yoshida, M. & Dickson, D. W. (2022). Neuropathology and emerging biomarkers in corticobasal syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 93(9), 919–929. https://doi.org/10.1136/JNNP-2021–328586,

  19. Koga, S. Roemer, S. F. Kasanuki, K. & Dickson, D. W. (2019). Cerebrovascular pathology presenting as corticobasal syndrome: An autopsy case series of «vascular CBS.» Parkinsonism and Related Disorders, 68,79–84. https://doi.org/10.1016/j.parkreldis. 2019.09.001

  20. Kovacs, G. G. Ferrer, I. Grinberg, L. T. Alafuzoff, I. Attems, J. Budka, H. Cairns, N. J. Crary, J. F. Duyckaerts, C. Ghetti, B. Halliday, G. M. Ironside, J. W. Love, S. Mackenzie, I. R. Munoz, D. G. Murray, M. E. Nelson, P. T. Takahashi, H. Trojanowski, J. Q. … Dickson, D. W. (2016). Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 131(1), 87–102. https://doi.org/10.1007/S00401–015–1509-X,

  21. Kovacs, G. G. Ghetti, B. & Goedert, M. (2022). Classification of Diseases with Accumulation of Tau Protein. Neuropathology and Applied Neurobiology, 48(3), e12792. https://doi.org/10.1111/NAN. 12792,

  22. Lee, M. C. Yang, Y. C. Chen, Y. C. Chang, B. S. Li, Y. C. & Huang, S. C. (2021). Epidemiology of atypical parkinsonian syndromes. Tzu-Chi Medical Journal, 34(2), 169. https://doi.org/10.4103/TCMJ. TCMJ_218_20,

  23. Lee, S. E. Rabinovici, G. D. Mayo, M. C. Wilson, S. M. Seeley, W. W. Dearmond, S. J. Huang, E. J. Trojanowski, J. Q. Growdon, M. E. Jang, J. Y. Sidhu, M. See, T. M. Karydas, A. M. Gorno-Tempini, M. L. Boxer, A. L. Weiner, M. W. Geschwind, M. D. Rankin, K. P. & Miller, B. L. (2011). Clinicopathological correlations in corticobasal degeneration. Annals of Neurology, 70(2), 327–340. https://doi.org/10.1002/ANA. 22424,

  24. Lu, J. Q. Fong, C. & Attar, A. (2020). Levodopa-responsive parkinsonism in a patient with corticobasal degeneration and bilateral choroid plexus xanthogranulomas. Journal of Clinical Neuroscience, 71,286–289. https://doi.org/10.1016/j.jocn. 2019.09.007

  25. Mathew, R. Bak, T. H. & Hodges, J. R. (2012). Diagnostic criteria for corticobasal syndrome: a comparative study. Journal of Neurology, Neurosurgery & Psychiatry, 83(4), 405–410. https://doi.org/10.1136/JNNP-2011–300875,

  26. Matsuda, K. Satoh, M. Tabei, K.ichi, Ueda, Y. Taniguchi, A. Matsuura, K. Asahi, M. Ii, Y. Niwa, A. & Tomimoto, H. (2020). Impairment of intermediate somatosensory function in corticobasal syndrome. Scientific Reports 2020 10:1,10(1), 1–8. https://doi.org/10.1038/s41598–020–67991–7,

  27. Moscovich, M. Boschetti, G. Moro, A. Teive, H. A. G. Hassan, A. & Munhoz, R. P. (2017). Death certificate data and causes of death in patients with parkinsonism. Parkinsonism and Related Disorders, 41,99–103. https://doi.org/10.1016/j.parkreldis. 2017.05.022,

  28. Müller, J. Wenning, G. K. Verny, M. McKee, A. Chaudhuri, K. R. Jellinger, K. Poewe, W. & Litvan, I. (2001). Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Archives of Neurology, 58(2), 259–264. https://doi.org/10.1001/ARCHNEUR. 58.2. 259,

  29. Olfati, N. Shoeibi, A. & Litvan, I. (2022). Clinical Spectrum of Tauopathies. Frontiers in Neurology, 13,944806. https://doi.org/10.3389/FNEUR. 2022.944806,

  30. Saeed, U. Compagnone, J. Aviv, R. I. Strafella, A. P. Black, S. E. Lang, A. E. & Masellis, M. (2017). Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts. Translational Neurodegeneration 2017 6:1,6(1), 1–25. https://doi.org/10.1186/S40035–017–0076–6,

  31. Schönecker, S. Palleis, C. Franzmeier, N. Katzdobler, S. Ferschmann, C. Schuster, S. Finze, A. Scheifele, M. Prix, C. Fietzek, U. Weidinger, E. Nübling, G. Vöglein, J. Patt, M. Barthel, H. Sabri, O. Danek, A. Höglinger, G. U. Brendel, M. & Levin, J. (2023). Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [18F]-PI-2620 tau-PET signal. NeuroImage: Clinical, 38. https://doi.org/10.1016/j.nicl. 2023.103402,

  32. Smith, A. D. Refsum, H. Bottiglieri, T. Fenech, M. Hooshmand, B. McCaddon, A. Miller, J. W. Rosenberg, I. H. & Obeid, R. (2018). Homocysteine and Dementia: An International Consensus Statement. Journal of Alzheimer’s Disease, 62(2), 561. https://doi.org/10.3233/JAD-171042,

  33. Sims, J. R. Zimmer, J. A. Evans, C. D. Lu, M. Ardayfio, P. Sparks, J. D. Wessels, A. M. Shcherbinin, S. Wang, H. Monkul Nery, E. S. Collins, E. C. Solomon, P. Salloway, S. Apostolova, L. G. Hansson, O. Ritchie, C. Brooks, D. A. Mintun, M. & Skovronsky, D. M. (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA, 330(6), 512. https://doi.org/10.1001/JAMA. 2023.13239,

  34. Stamelou, M. Alonso-Canovas, A. & Bhatia, K. P. (2012). Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases. Movement Disorders : Official Journal of the Movement Disorder Society, 27(6), 696–702. https://doi.org/10.1002/MDS. 24992,

  35. Tsai, R. M. Miller, Z. Koestler, M. Rojas, J. C. Ljubenkov, P. A. Rosen, H. J. Rabinovici, G. D. Fagan, A. M. Cobigo, Y. Brown, J. A. Jung, J. I. Hare, E. Geldmacher, D. S. Natelson-Love, M. McKinley, E. C. Luong, P. N. Chuu, E. L. Powers, R. Mumford, P. … Boxer, A. L. (2019). Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial. JAMA Neurology, 77(2), 215. https://doi.org/10.1001/JAMANEUROL. 2019.3812,

  36. Uchihara, T. (2014). Pretangles and neurofibrillary changes: Similarities and differences between AD and CBD based on molecular and morphological evolution. Neuropathology, 34(6), 571–577. https://doi.org/10.1111/NEUP. 12108,

  37. U. S. Social Security Administration. Program Operations Manual System (POMS). https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022605. Accessed June 6,2025.

  38. VandeVrede, L. Ljubenkov, P. A. Rojas, J. C. Welch, A. E. & Boxer, A. L. (2020). Four-Repeat Tauopathies: Current Management and Future Treatments. Neurotherapeutics, 17(4), 1563. https://doi.org/10.1007/S13311–020–00888–5,

  39. Vanek, Z. & Jankovic, J. (2001). Dystonia in corticobasal degeneration. Movement Disorders, 16(2), 252–257. https://doi.org/10.1002/mds. 1038,

  40. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975 May; 72(5): 1858–62.doi: 10.1073/pnas. 72.5. 1858. PMID: 1057175; PMCID: PMC432646.

  41. Wenning, G. K. Litvan, I. Jankovic, J. Granata, R. Mangone, C. A. McKee, A. Poewe, W. Jellinger, K. Chaudhuri, K. R. D’Olhaberriague, L. & Pearce, R. K. B. (1998). Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. Journal of Neurology, Neurosurgery, and Psychiatry, 64(2), 184. https://doi.org/10.1136/JNNP. 64.2. 184,

  42. Wilson, D.le Heron, C. & Anderson, T. (2021). Corticobasal syndrome: a practical guide. Practical Neurology, 21(4), 276–285. https://doi.org/10.1136/PRACTNEUROL-2020–002835

  43. Winter, Y. Bezdolnyy, Y. Katunina, E. Avakjan, G. Reese, J. P. Klotsche, J. Oertel, W. H. Dodel, R. & Gusev, E. (2010). Incidence of Parkinson’s disease and atypical parkinsonism: Russian population-based study. Movement Disorders : Official Journal of the Movement Disorder Society, 25(3), 349–356. https://doi.org/10.1002/MDS. 22966,

  44. Zhang, X. Gao, F. Wang, D. Li, C. Fu, Y. He, W. & Zhang, J. (2018). Tau Pathology in Parkinson’s Disease. Frontiers in Neurology, 9(OCT), 809. https://doi.org/10.3389/FNEUR. 2018.00809

  45. Zhang, W. Tarutani, A. Newell, K. L. Murzin, A. G. Matsubara, T. Falcon, B. Vidal, R. Garringer, H. J. Shi, Y. Ikeuchi, T. Murayama, S. Ghetti, B. Hasegawa, M. Goedert, M. & Scheres, S. H. W. (2020). Novel tau filament fold in corticobasal degeneration. Nature, 580(7802), 283–287. https://doi.org/10.1038/S41586–020–2043–0,

  46. Васенина Е. Е. Левин О. С. Современные подходы к клинической диагностике и лечению мультисистемных дегенераций, связанных с накоплением тау-протеина. Журнал неврологии и психиатрии им. С. С. Корсакова. Спецвыпуски. 2020; 120(10‑2): 22‑30.

  47. Ткачева О. Н. Яхно Н. Н. Незнанов Н. Г. Шпорт С. В. Шамалов Н. А. Левин О. С. Костюк Г. П. Гусев Е. И. Мартынов М. Ю. Гаврилова С. И. Котовская Ю. В. Мхитарян Э. А. Чердак М. А. Колыхалов И. В. Шмуклер А. Б. Пищикова Л. Е. Боголепова А. Н. Литвиненко И. В. Емелин А. Ю. Лобзин В. Ю. Васенина Е. Е. Залуцкая Н. М. Захаров В. В. Преображенская И. С. Курмышев М. В. Савилов В. Б. Исаев Р. И. Чимагомедова А. Ш. Дудченко Н. Г. Пальчикова Е. И. Гомзякова Н. А. Занин К. В. Клинические рекомендации «Когнитивные расстройства у лиц пожилого и старческого возраста». Журнал неврологии и психиатрии им. С. С. Корсакова. 2025; 125(3–3): 7–149. https://doi.org/10.17116/jnevro2025125337

Шпилюкова Ю. А. Федотова Е. Ю. Иллариошкин С. Н. (2022). Кортикобазальный синдром как фенотипическое проявление различных нейродегенеративных заболеваний: описание серии случаев. Анналы Клинической и Экспериментальной Неврологии, 16(1), 64–70. https://doi.org/10.17816/ACEN836–625

Меню сайта